Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
JENNIFER J. KISER, PHARM.D. University of Colorado Denver School of Pharmacy Department of Pharmaceutical Sciences 12700 East 19th Avenue, P15-C238 Aurora, CO 80045 Office (303) 724-6131 Laboratory (303) 724-6132 Fax (303) 724-6135 Cellular (720) 219-9324 Email [email protected] EDUCATION August 2003-present Graduate Coursework (12 hours, GPA 3.9) University of Colorado Denver BIOM 6601: Biostatistics Methods I BIOM 6602: Biostatistics Methods II BIOM 6648: Clinical Trial Design TXCL 7655: Pharmacokinetics and Toxicokinetics BIOM 6680: SAS Programming for Data Management CLSC 7150: Ethics and Regulation in Human Subjects Review CLSC 6270: Critical Appraisal Seminars in Clinical Science CLSC 6650: Guided Research Tutorial August 1997- May 2001 Doctor of Pharmacy University of North Carolina Chapel Hill Chapel Hill, North Carolina TRAINING AND PROFESSIONAL EXPERIENCE Licensure Registered Pharmacist. State of California. RPH #53383 Registered Pharmacist, State of Colorado. RPH # 16688 Registered Pharmacist, State of North Carolina. RPH # 17121 Antiretroviral Clinical Pharmacology Fellow UNIVERSITY OF COLORADO DENVER; Department of Clinical Pharmacy Denver, Colorado July 1, 2003-January 31, 2006 Supervisor: Courtney V. Fletcher, Pharm.D. Activities: hypothesis generation and study design, grant preparation, wrote protocols and consent forms, designed case report forms, communicated with the NIH, Clinical Research Center, and Institutional Review Boards (IRB), recruited and consented study subjects, conducted patient study visits, maintained patient records and electronic study database, managed NIH site visits/study audits, conducted IRB annual reviews, and compiled safety/laboratory data for safety officer reviews, pharmacokinetic modeling, scientific presentations, manuscript preparation and submission to scientific journals, manuscript review for scientific journals, teaching, provided antiretroviral concentration interpretation and antiretroviral drug information to HIV providers locally and nationally Outpatient Clinical Pharmacist JOHNS HOPKINS HOSPITAL, Outpatient HIV Clinic, Moore Clinic Baltimore, Maryland September 1, 2003-June 27, 2003 Supervisor: None Jennifer J. Kiser, PharmD Page 1 of 9 06/30/17 Activities: developed a pharmacist-managed clinic at the Johns Hopkins Outpatient HIV clinic with three other pharmacists, provided basic HIV education to patients regarding medications, VL/CD4 measures, opportunistic infections, etc., initiated patients on antiretroviral drugs, developed medication schedules and filled pillboxes for patients, assisted patients with antiretroviral side effect management, assessed adherence with both opportunistic infection medications and antiretroviral drugs, directly observed therapy for select patients, educated patients on preparing and administering enfuvirtide Inpatient Clinical Pharmacist JOHNS HOPKINS HOSPITAL, Department of Pharmacy Baltimore, Maryland July 22, 2002-June 27, 2003 Supervisor: Connie Saltsman, Pharm.D. Activities: clinical pharmacist for HIV/Opportunistic Infections unit and one general medicine unit, staffed in pharmacy satellite, code response team, provided inservices/CEs, served on medication safety committees, developed policies/procedures for the use of thalidomide and enfuvirtide, provided discharge counseling to patients on the HIV/Opportunistic Infections unit Pharmacy Practice Resident (ASHP Accredited) UNIVERSITY OF CALIFORNIA SAN DIEGO MEDICAL CENTER, Department of Pharmacy San Diego, California July 1, 2001-June 30, 2002 Supervisor: Charles James, Pharm.D. Activities: clinical rotations in inpatient infectious diseases, outpatient pharmacist-managed antiretroviral clinic, ambulatory care (warfarin, asthma, CHF, transplant clinics), home infusion, internal medicine, medical intensive care, trauma/surgical intensive care, neonatal intensive care, pharmacokinetics, drug information and two six-month longitudinal outpatient clinic rotations in the pharmacist-managed antiretroviral clinic and the HIV lipid/lipodystrophy clinic, performed a medication use evaluation of nosocomial pneumonia treatment, resident research study evaluating outcomes of patients in the tenofovir expanded access program at our institution, two grand rounds presentations, one platform presentation at Western States Intern GLAXO WELLCOME INC., US Medical Affairs Research Triangle Park, North Carolina May 15, 2000-July 28, 2000 Full-time during summer Supervisor: Timothy Kuhn, Pharm.D. Activities: researched and wrote a review article on serotonin agonists (triptans) to be submitted to a scientific journal, organized study data into study files, updated budget spreadsheet for approximately 100 studies Intern GLAXO WELLCOME INC., World Wide Clinical Genetics Research Triangle Park, North Carolina January 2000-May 2000 Part-time during school Supervisor: Wayne Anderson, Ph.D. Activities: wrote final study reports based on incoming data from genetic components of clinical trials, attended scientific meetings, interacted with other Glaxo Wellcome employees in Commercial Operations, US Medical Affairs, and Laboratory Operations Intern GLAXO WELLCOME INC., US Health Outcomes Research Triangle Park, North Carolina November 1998-December 1999 Full-time during summers, part-time during school Supervisor: Richard Stanford, Pharm.D. Jennifer J. Kiser, PharmD Page 2 of 9 06/30/17 Activities: summarized clinical, quality-of-life, and cost-analysis studies for sales force and other health care professionals, wrote, edited, and assisted in submission of potential publications, researched and reported data on ICD-9/10 codes, took minutes at scientific meetings, assisted in evaluation and implementation of economic models and patient questionnaires, set up new publication alerts for various therapeutic areas, conducted extensive literature searches and summarized findings (specific projects included obesity, irritable bowel syndrome, and HIV lipodystrophy syndrome), organized study data into files, maintained study files Intern GLAXO WELLCOME INC., Clinical Applications Research Research Triangle Park, North Carolina May 1996-November 1998 Full-time during summers, part-time during school Supervisor: Janet L. Fox, Pharm.D. Activities: wrote and edited protocols, abstracts, manuscripts, final study reports, case report forms, and subject consent forms, entered and analyzed study data from Case Report Forms, updated Study Status Reports, presented study updates at Review Committee Meetings, created and maintained the departmental budget spreadsheet for approximately 500 studies, interacted with potential investigators and sales representatives, organized study data into files, maintained study files, conducted literature searches, maintained a potential investigator database ACADEMIC APPOINTMENTS March 1, 2008 to present Graduate Faculty (Toxicology), University of Colorado Denver School of Pharmacy February 1, 2008 to present Assistant Professor, Department of Pharmaceutical Sciences, University of Colorado Denver School of Pharmacy February 1, 2006-January 31, 2008 Research Assistant Professor, Department of Pharmaceutical Sciences, University of Colorado Denver School of Pharmacy CONSULTING ACTIVITY April 2009 Bristol Myers Squibb, The Collaborative Institute of Virology’s Pediatrics Panel TEACHING AND LECTURING EXPERIENCE Graduate and Undergraduate University of Colorado Denver, Aurora, CO December 2009 P3 Fall Seminar PHRD 5200A Fall 2009 P3 Integrated Organ Systems XI (9 hours) October 2009 P2 Clinical Sciences Foundations PHRD 4600 (2.5 hours) Spring 2009 Interdisciplinary Ethics Course, PRMD 5000 (10 hours) April 2009 Drug Metabolism & Pharmacogenetics, TXCL 7561 (1 hour) February 2009 Principles of Drug Action, PHRD 3650 (1.5 hr) Fall 2008 P3 Integrated Organ Systems XI (8 hours) April 2008 TXCL 7561 Drug Metabolism & Pharmacogenetics (1 hour) March 2008 Comprehensive Patient Care PHRD 5650 (8 hours) February 2008 P3 Spring Seminar PHRD 5200B November 2007 P3 Integrated Organ Systems XI (8 hours) Spring 2007 P3 Spring Seminar PHRD 5200B December 2006 Professional Skills Development PHRD 5100 November-December 2006 P3 Integrated Organ Systems XI November 2005 P3 Integrated Organ Systems XI October 2005 P2 Clinical Sciences Foundations PHRD 4600 Fall 2005 P3 Fall Seminar PHRD 5200A April 2005 Comprehensive Patient Care PHRD 5650 December 2004 Professional Skills Development PHRD 5100 Fall 2004-Spring 2005 P4 Advanced Pharmaceutical Care Portfolio PHRD 6100 Fall 2004 P3 Fall Seminar PHRD 5200A April 2004 Comprehensive Patient Care PHRD 5650 Jennifer J. Kiser, PharmD Page 3 of 9 06/30/17 November 2003 Professional Skills Development PHRD 5100 Johns Hopkins School of Nursing, Baltimore, MD January 16, 2003 Pharmacologic Management of HIV-100.401 Adult Physical Health University of California San Diego Medical Center, San Diego, CA July 2001-June 2002 Preceptor-CP148. UCSF School of Pharmacy December 2001-February 02 California Pharmacy Board Review for UCSF pharmacy students University of North Carolina Wilmington, Wilmington, NC Spring Semester 2001 Advanced Pharmacotherapy for Nurse Practitioners NSG 512 Continuing Education 2007 2007 2005 MediMax Communications (physicians) Colorado Pharmacists Society Medscape CME (physicians) ADVISING ACTIVITY Professional Program (Pharm.D.) June 2008-present Kevin Henderson, P2, Honors Project, Clinical Research May 2008-present Jessica Bannon, P2, student worker, Clinical Research Summer 2009 Brock Bumpass, P2, student worker and Masters Thesis, Clinical Research 2008 Alyssa Walker, P3 and P4 years, Clinical Research UNIVERSITY SERVICE 2009 June 2009 2008-present Conflict of Interest Committee, University of Colorado Denver School of Pharmacy Department of Pharmaceutical Sciences Retreat Planning and Organizing Committee Admissions Committee, University of Colorado Denver School of Pharmacy SPECIAL ASSIGNMENTS May 2008 to present October 2007 to present Investigator-at-Large, AIDS Clinical Trials Group (ACTG) Hepatitis Committee Medical Advisor, Colorado AIDS Drug Assistance Program Formulary Committee November 2007 to September 2009 AIDS Clinical Trials Group (ACTG) Hepatic Function Working Group HONORS AND AWARDS 2006 Conference on Retroviruses and Opportunistic Infections Young Investigator Award 2004-2005 Recipient of the American College of Clinical Pharmacy Ortho-McNeil Pharmaceutical Infectious Diseases Fellowship 2002 Recipient of Shining Star Practitioner Recognition Award at Johns Hopkins Hospital 2002 Recipient of the University of California San Diego Resident Research Award 2000-2001 Recipient of the George T. Cornwell Pharmacy Scholarship 2000 Recipient of the Ralph Rogers Sr. Pharmaceutical Policy and Evaluative Sciences Administration Award 1999-2000 Recipient of the J. Lee and Helen Yingling Pharmacy Scholarship University of North Carolina Dean’s List PROFESSIONAL ACTIVITY AND PUBLIC SERVICE Organization Memberships January 2008 to present American Association for the Study of Liver Diseases April 2007 to present American Association of Colleges of Pharmacy August 2004 to present Society of Infectious Diseases Pharmacists July 2001 to present American College of Clinical Pharmacy Review Panels June 2009 Grant Reviewer, NIH Challenge Grants in Health and Science Research June 2008 Grant Reviewer, University of California San Diego Center for AIDS Research May 2008 Grant Reviewer, NIDA, NIH, Drug Interactions Special Emphasis Panel Journal Referee AIDS Research and Human Retroviruses Jennifer J. Kiser, PharmD Page 4 of 9 06/30/17 Antimicrobial Agents and Chemotherapy Antiviral Therapy Clinical Infectious Diseases Clinical Pharmacokinetics Clinical Pharmacology and Therapeutics Expert Review of Anti-infective Therapy Expert Opinion on Drug Metabolism & Toxicology Expert Opinion on Investigational Drugs Expert Opinion on Pharmacotherapy HIV Clinical Trials Journal of Acquired Immunodeficiency Syndrome Pharmacogenetics and Genomics Pharmacogenomics Pharmacotherapy SPEAKING ENGAGEMENTS Local 1. 2. 3. 4. 5. 6. 7. 8. 9. 10. 11. 12. 13. 14. 15. 16. 17. 18. “Emerging Treatments for Hepatitis C Virus” Colorado HIV/AIDS Community Advisory Board, 12/09, Aurora, CO. “Sex Differences in Antiretroviral Drug Pharmacokinetics and Toxicities and Antiretroviral Drug Interactions Important for Women.” Clinical Care of HIV-Infected Women Symposium, 4/07, Denver, CO. “Pharmacology Update from the Conference on Retroviruses and Opportunistic Infections.” Colorado HIV/AIDS Community Advisory Board, 3/07, Denver, CO. “The Effect of Lopinavir/Ritonavir on the Renal Clearance of Tenofovir”. Center for AIDS Research, 2/06, Denver, CO. “The Effects of Low Dose Ritonavir on the Renal Clearance of Tenofovir”. University of Colorado Department of Clinical Pharmacy Faculty Retreat, 8/04, Vail, CO. “Enfuvirtide Use at Johns Hopkins Hospital”. The Johns Hopkins Hospital Department of Pharmacy and Nursing InService, 6/03, Baltimore, MD. “Antiretrovirals”. The Johns Hopkins Hospital Department of Pharmacy, General Medicine Pharmacists, 4/03, Baltimore, MD. “Pharmacologic Management of Alcohol and Opioid Withdrawal”. Nursing In-Service, Johns Hopkins Hospital, 12/02, Baltimore, MD. “Adverse Drug Reactions”. Nursing In-Service, Johns Hopkins Hospital, 11/02, Baltimore, MD. “SSRI Withdrawal Syndrome”. The Johns Hopkins Hospital Clinical Pharmacology Forum, 10/02, Baltimore, MD. “Nevirapine-Induced Stevens-Johnson Syndrome”. Pharmacy Morbidity and Mortality Rounds, UCSD Department of Pharmacy, 6/02, San Diego, CA. “Voriconazole”. Pharmacy Grand Rounds, UCSD Department of Pharmacy, 11/01, San Diego, CA. “Pharmacotherapy Update in the Treatment of Mycobacterium Avium Complex in patients with AIDS” Pharmacy Department, National Institutes of Health Clinical Center, 4/01, Bethesda, MD. “Short-Term Use of Octreotide for the Treatment of Gastrointestinal Bleeding in Children”. Pediatric Pharmacy Department, Duke University Regional Medical Center, 2/01, Durham, NC. “Initiating Pharmacologic Treatment in Hepatitis C”. Pharmacy Student Seminar, Coastal Area Health Education Center, 1/01, Wilmington, NC. “Electronic Submissions at the Food and Drug Administration”. FDA Drug Information Department, 10/00, Rockville, MD. “Prilosec 1™: Summary of Proceedings of the Joint Nonprescription and Gastrointestinal Drugs Committees FDA Advisory Meeting”. FDA Drug Information Department, 10/00, Rockville, MD. “Internet Pharmacies: Strategic Initiatives for Glaxo Wellcome”. Group presentation to a division of Commerical Operations, Glaxo Wellcome Inc. as part of Drug Discovery, Development, and Marketing Seminar through UNC School of Public Health, 12/99, RTP, NC. National 1. 2. “Pharmacokinetics (PK) and Genetics (PG) of Isoniazid (INH) in South African HIV-Exposed Infants-PACTG 1041”. 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. Abstract 1680, October 27, 2008. Washington DC. “ATN 056: Pharmacokinetics of Antiretroviral Regimens Containing Tenofovir and Atazanavir/Ritonavir in Adolescents and Young Adults with HIV Infection”. Adolescent Treatment Network Meeting, October 4, 2006. Silver Spring, MD. Jennifer J. Kiser, PharmD Page 5 of 9 06/30/17 3. 4. 5. 6. 7. “PACTG 1020 Atazanavir with and without Ritonavir in HIV-Infected Infants, Children, and Adolescents”. Bristol Myers Squibb Collaborative Institute of Virology, June 24, 2006. Dallas, TX. “The Effects of Lopinavir/Ritonavir on the Renal Clearance of Tenofovir”. Charleston Fellow Forum, June 2-5, 2005. Charleston, SC. “NRTI Interactions with Other Antiretroviral Drugs: Clinical Studies”. World Health CME Content Development Meeting, March 2005, Dallas, TX. “Pharmacokinetics of Atazanavir/ritonavir (ATV/RTV) in HIV-Infected Infants, Children, and Adolescents: Pediatric AIDS Clinical Trial Group 1020B.” Vail Fellow Forum, June 3-6, 2004. Vail, CO. “Tenofovir: Efficacy in an Expanded Access Program”. Western States Residency Convention, May 2002, Monterey, CA. International 1. 2. 3. “Pharmacokinetics (PK) of antiretroviral regimens containing Tenofovir Disoproxil Fumarate (TDF) and Atazanavir/Ritonavir (ATV/RTV) in adolescents and young adults with HIV Infection – Study ATN056”. 8th International Workshop on Clinical Pharmacology of HIV Therapy. Abstract 12. April 16-18, 2007. Budapest, Hungary. “Effect of Multidrug Resistance Proteins 2 and 4 Polymorphisms on Tenofovir Pharmacokinetics in HIV-Infected Patients.” 7th International Workshop on the Clinical Pharmacology of HIV Therapy. Abstract #34. April 20-22, 2006. Lisbon, Portugal. “Antiretroviral Drug Dose and Formulation Challenges in Children”. Pediatric Formulations for Antiretroviral Therapies: A Forum for Collaborative HIV Research Workshop. April 28, 2005. Quebec City, Canada. RESEARCH ACTIVITY Active Aug 2009-July 2014 March 2008-Feb 2010 March 2007-present April 2009-present July 2009-present March 2007-present January 2006-present Principal Investigator: 5K23DK082621-02 NIH, NIDDK Concentration-Controlled Ribavirin for the Treatment of Patients with Chronic HCV Total Direct Costs: $777,489 Protocol Pharmacologist: Adolescents Treatment Network Study 063 (PI: Havens PL) Randomized, placebo-controlled trial of the Safety and Effectiveness of Vitamin D Supplement to Improve Tubular Reabsorption of Phosphate and Decrease bone turnover in Adolescents and Young Adults with HIV infection being treated with Antiretroviral Therapy Containing Tenofovir Compared to Those being treated with Antiretroviral Therapy not Containing Tenofovir Total Award Amount: ~$14,000 (5% effort only) Principal Investigator: University of Colorado Department of Pharmaceutical Sciences Seed Grant In Vitro Evaluation of an Intracellular Drug-Drug Interaction between Entecavir and Ribavirin Total Award Amount: $14,623 Faculty Mentor: COMIRB 08-1198 (student/PI: Kevin Henderson) Assessing the Effectiveness of Pharmacy Based Adherence Interventions on Adherence in Persons with HIV Total Award Amount: $3000 from DOPS to student Principal Investigator: COMIRB 09-0475/CTRC 6004 Effect of Antacids on the Pharmacokinetics of Raltegravir in Healthy Volunteers (unsponsored) Co-Investigator, Protocol Pharmacologist: COMIRB 06-1178 (PI: Carten MC) A Pilot Study of the Pharmacokinetic Interaction between the hormonal emergency contraception, Plan B, and efavirenz (unsponsored) Co-Investigator, Protocol Pharmacologist: Pediatric AIDS Clinical Trial Group Study 1041 (PI: Nachman S) A Randomized Double Blind, Placebo Controlled Trial to Determine the Efficacy of Isoniazid in Preventing Tuberculosis Disease and Latent Tuberculosis Infection Among South African Infants with Perinatal Exposure to HIV (unsponsored) Jennifer J. Kiser, PharmD Page 6 of 9 06/30/17 October 2003-present Co-Investigator, Protocol Pharmacologist: Pediatric AIDS Clinical Trials Group Study 1020A (PI: Rutstein R) Pharmacokinetics and Safety Analysis of Atazanavir and Atazanavir/Ritonavir in HIVInfected Infants, Children, and Adolescents (unsponsored) Completed January 2008-June 2009 Co-Investigator: Tibotec Investigator-Initiated Study (PI: Aquilante CL) Genetic predictors of pharmacokinetic variability in the drug-drug interaction between darunavir/ritonavir and pravastatin: the role of SLCO1B1 polymorphisms Annual Direct Costs: $168,761 May 2008-April 2009 Co-Investigator: P30 AI054907, NIH, NIAID (PI: Campbell T) Colorado Center for AIDS Research Total Direct Costs: $555,070 Dec 2005-Dec 2008 Principal Investigator: Colorado Center for AIDS Research Junior Faculty Award Pharmacologic Evaluation of HIV-Infected Pregnant Women on Highly Active Antiretroviral Therapy Total Award Amount: $50,000 Dec 2005-April 2008 Co-Investigator: P30 AI054907-02S1 (PI: Fletcher CV, McFarland E) Effects of Puberty on Antiretroviral Drug Metabolism in HIV Infected Children and Adolescents Award Amount: $216,631/yr direct costs August 2005-Feb 2007 Protocol Pharmacologist/Protocol Vice Chair: Adolescents Treatment Network Study 056 (PI: Havens PL) Pharmacokinetics of Once Daily Antiretroviral Therapy Regimens Containing Tenofovir and Atazanavir in Adolescents and Young Adults with HIV Infection. Total Award Amount: $74,498 August 2005-March 2007 Co-Investigator: AstraZeneca investigator-sponsored study (PI: Hoody DW, Gerber JG) Evaluation of Pharmacokinetic Interactions Between Crestor and the Combination Protease Inhibitor Kaletra Total Award Amount: $225,595 July 2004-June 2005 Principal Investigator: ACCP Ortho-McNeil Pharmaceutical Infectious Diseases Fellowship The Effect of Low-dose Ritonavir on the Renal Clearance of Tenofovir Total Award Amount: $31,500 January 2004-Dec 2006 Co-Investigator: NIH R01 A133835-10 (PI: Fletcher CV) Concentration-Controlled Antiretroviral Therapy in Persons Experiencing Persistent Viremia Award Amount: $200,000/yr direct costs July 2001-June 2002 Medication Utilization Evaluation: Treatment of Nosocomial Pneumonia UCSD Medical Center July 2001-May 2002 Early CD4, viral load, and safety outcomes with tenofovir (Viread) USCD Medical Center Owen Clinic PUBLICATIONS Refereed 1. 2. 3. 4. 5. Kiser JJ. Practice guidelines: development, application to clinical care, and role in provider education. Clin Pharmacol Ther. 2009;86(3):239-41. Brousseau KM, Filley CM, Kaye K, Kiser JJ, Adler LE, Connick E. Dementia with features of Alzheimer's disease and HIV-associated dementia in an elderly man with AIDS. AIDS 2009;23(8):1029-31. Kiser JJ, Gerber JG, Predhomme JA, Wolfe P, Flynn DM, Hoody DW. Drug : Drug Interaction Between Lopinavir/Ritonavir and Rosuvastatin in Healthy Volunteers. JAIDS 2008; 47(5):570-578. Kiser JJ, Aquilante CL, Anderson PL, King T, Carten ML, Fletcher CV. Clinical and Genetic Determinants of Intracellular Tenofovir Diphosphate Concentrations in HIV-Infected Patients. JAIDS 2008; 47(3):298-303. Kiser JJ, Fletcher CV, Flynn PM, Cunningham CK, Wilson CM, Kapogiannis BG, Major-Wilson H, Viani RM, Liu NX, Muenz LR, Harris RD, Havens PL, and the Adolescent Trials Network for HIV/AIDS Interventions. Jennifer J. Kiser, PharmD Page 7 of 9 06/30/17 6. 7. 8. 9. Pharmacokinetics of Antiretroviral Regimens Containing Tenofovir Disoproxil Fumarate and Atazanavir/Ritonavir in Adolescents and Young Adults with HIV Infection – ATN056. Antimicrobial Agents and Chemotherapy 2008;52(2):631-7. Kiser JJ, Carten ML, Aquilante CL, Anderson PL, Wolfe P, King TM, Delahnuty T, Bushman L, Fletcher CV. The Effect of Lopinavir/Ritonavir on the Renal Clearance of Tenofovir in HIV-Infected Patients. Clinical Pharmacology and Therapeutics 2008;83(2):265-272. Anderson, PL, Lichtenstein KA, Gerig NE, Kiser JJ, Bushman LR. Atazanavir-Containing Renal Calculi in an HIVInfected Patient. AIDS 2007;21(8):1060-1062. King T, Bushman L, Kiser J, Anderson PL, Ray M, Delahunty T, Fletcher CV. Liquid chromatography-tandem mass spectrometric determination of tenofovir-diphosphate in human peripheral blood mononuclear cells. J Chromatogr B Analyt Technol Biomed Life Sci. 2006;843(2):147-56. Kiser JJ, Lichtenstein KA, Anderson PL, Fletcher, CV. Case Report: The Effects of Esomeprazole on the Pharmacokinetics of Atazanavir and Fosamprenavir in an HIV-Infected Patient. Pharmacotherapy 2006;26(4):511-4. Non-Refereed 1. Kiser JJ, Anderson PL, Gerber JG. Therapeutic Drug Monitoring: Pharmacologic Considerations for Antiretroviral Drugs. Current HIV/AIDS Reports 2005; 2(2):61-7. Review Articles 1. 2. 3. 4. Kiser JJ. Trends in the Treatment of Chronic Hepatitis C Virus. Journal of Pharmacy Practice 2009;22:405-418. *continuing education for Pharmacists* Kiser JJ. Pharmacologic Characteristics of Investigational and Recently-Approved Agents for the Treatment of the Human Immunodeficiency Virus (HIV). Current Opinion in HIV and AIDS 2008;3:330-341. Kakuda TN, Kiser JJ. 7th International Workshop on Clinical Pharmacology of HIV Therapy. Expert Opinion on Pharmacotherapy 2006;7(11):1519-33. Kiser JJ, Anderson PL, Kakuda TN. 6th International Workshop on Clinical Pharmacology of HIV Therapy. Expert Opinion on Pharmacotherapy 2006;7(2):229-241. Book Chapters 1. 2. 3. Kiser JJ, Anderson PL, Fletcher CV. Chapter 139: HIV and Hepatitis C Coinfection. Pharmacotherapy Workbook: A Patient-Focused Approach, 7/e. McGraw-Hill 2008. Kiser JJ, Fletcher CV. Chapter 14: The Clinical Pharmacology of Nucleoside Reverse Transcriptase Inhibitors. Antimicrobial Pharmacodynamics in Theory and Clinical Practice, 2/e. Informa Healthcare, Inc. 2007 Kiser JJ, Anderson PL, Fletcher CV. Chapter 138: HIV and Hepatitis C Coinfection. Pharmacotherapy Workbook: A Patient-Focused Approach, 6/e. McGraw-Hill 2005. Abstracts/Poster Presentations 1. 2. 3. 4. 5. 6. 7. 8. Bannon JA, Aquilante CL, Hoody DW, Predhomme JA, Foster CJ, Walker A, Hammond K, Kiser JJ*. Effect of Transporter Genetics on Rosuvastatin Pharmacokinetics and the Magnitude of the Drug-Drug Interaction Between Rosuvastatin and Lopinavir/Ritonavir in Healthy Volunteers. American College of Clinical Pharmacy; October 17-21, 2009, Anaheim, CA [abstract 319 ]. Kiser JJ*, MaWhinney S, Kinzie K, Barr E, Simons A, Paul S, Hoody DW, Fletcher CV, Allshouse AA, Weinberg A. Total and Unbound Lopinavir/Ritonavir (LPV/RTV) Pharmacokinetics (PK) in a Concentration-Guided Study of HIVInfected Women Throughout Pregnancy and Post-partum (PP). 16th Conference on Retroviruses and Opportunistic Infections, Montreal, Canada [abstract 946]. Walker AM, Aquilante CL, Anderson PL, Foster CJ, Kiser JJ*. Lopinavir/ritonavir (LPV/RTV) pharmacokinetics (PK) in human immunodeficiency virus (HIV)-infected cytochrome P450 (CYP) 3A5 expressors versus nonexpressors. 2008 Spring Research and Practice Forum of the American College of Clinical Pharmacy; April 4-9, 2008; Phoenix, AZ [Poster #173]. Brousseau K, Connick E, Kaye K, Kiser JJ, Adler L, Filley CM. Cognitive Impairment in the Aging HIV-Infected Patient. American Neuropsychiatric Association 19th Annual Meeting, March 1-4, 2008, Savannah, GA. Fletcher CV, King TM, Bushman LR, Kiser JJ, Anderson PL, Brenchley J, Douck D, Schaker T. Compartment Kinetics of Intracellular Tenofovir. 15th Conference on Retroviruses and Opportunistic Infections, Boston, MA [abstract 754]. Hoody D, Kiser JJ, Predhomme J, Flynn D, Gerber J. Drug-Drug Interaction between Lopinavir/Ritonavir and Rosuvastatin. 14th Conference on Retroviruses and Opportunistic Infections, February 25-28, 2007, Los Angeles, CA [abstract 564]. Rutstein R, Samson P, Kiser J, Fletcher CV, Graham B, Schnittman S, Smith M, Mofenson L, Fenton T, Aldrovandi G. The PACTG 1020A Protocol: Atazanavir with or without ritonavir in HIV-infected infants, children, and adolescents. 14th Conference on Retroviruses and Opportunistic Infections, February 25-28, 2007, Los Angeles, CA [abstract 715]. Kiser JJ, Carten MC, Wolfe P, King TM, Delahunty T, Bushman LR, Anderson PL, Fletcher CV*. The Effect of Lopinavir/Ritonavir on the Renal Clearance of Tenofovir in HIV-Infected Patients. 13th Conference on Retroviruses and Opportunistic Infections, February 5-9, 2006, Denver, CO [poster 570]. Jennifer J. Kiser, PharmD Page 8 of 9 06/30/17 9. 10. 11. 12. 13. 14. P Samson P, R Rutstein, T Fenton, J Kiser, CV Fletcher, S Schnittman, L Mofenson, E Smith, B Graham, G Aldrovandi and the PACTG 1020 Study Team. Changes in Cholesterol and Triglyceride Levels among Pediatric Patients Treated with Atazanavir, With or Without Ritonavir Boosting, the 1020A NIH PACTG Protocol. 13 th Conference on Retroviruses and Opportunistic Infections, February 5-9, 2006, Denver, CO [poster 689]. Kiser JJ, Carten MC, Anderson PL, Fletcher CV*. The Effects of Lopinavir/Ritonavir on the Renal Clearance of Tenofovir. 8th Annual Conference on Infectious Diseases Pharmacotherapy: Making a Difference, May 12-15 2005. Poster Presentation. J Kiser, R Rutstein, G Aldrovandi, P Samson, B Graham, S Schnittman, M Smith, L Mofenson, CV Fletcher*, and the PACTG 1020 Study Team. Pharmacokinetics of Atazanavir/Ritonavir in HIV-Infected Infants, Children, and Adolescents: PACTG 1020A. 12th Conference on Retroviruses and Opportunistic Infections, February 22-25, 2005, Boston, MA [poster 767]. R Rutstein, P Samson, G Aldrovandi, B Graham, S Schnittman, CV Fletcher, J Kiser, E Smith, L Mofenson, T Fenton, and the PACTG 1020A Study Team. Effect of Atazanavir on Serum Cholesterol and Triglyceride Levels in HIVInfected Infants, Children, and Adolescents: PACTG 1020A. 12th Conference on Retroviruses and Opportunistic Infections, February 22-25, 2005, Boston, MA [poster 774]. “Pharmacokinetics of Atazanavir/ritonavir (ATV/RTV) in HIV-Infected Infants, Children, and Adolescents: Pediatric AIDS Clinical Trial Group 1020B. 7th Annual Conference on Infectious Diseases Pharmacotherapy: Making a Difference, May 13-16 2004. Poster Presentation. Schwartz RH, Wright S, Justice JA, Deeter RG. Taste Preferences of Less Pleasant-Tasting Antibiotic Suspensions in Children with Acute Otitis Media and Tonsillitis. Clinical Infectious Diseases 1998;27(4):920, Abstract #751. Letters 1. Kiser JJ, Fletcher CV. Response to "Lack of Evidence for an Effect of Lopinavir/Ritonavir on Tenofovir Renal Clearance". Clin Pharmacol Ther 2008; 84(6):661. Others 1. 2. 3. 4. 5. 6. 7. 8. 9. Kiser JJ. Meeting Report: the 4th International Workshop on Clinical Pharmacology of Hepatitis Therapy. National AIDS Treatment Assistance Program, July 12, 2009. Kiser JJ. Meeting Report: the 3rd International Workshop on Clinical Pharmacology of Hepatitis Therapy. National AIDS Treatment Assistance Program, April 22, 2008. Kiser JJ, Fletcher CV. Meeting Report: the 9th International Workshop on Clinical Pharmacology of HIV Therapy. National AIDS Treatment Assistance Program, April 22, 2008. Kiser JJ, Fletcher CV. Pharmacology Update from the 8th International Workshop on Clinical Pharmacology of HIV Therapy. National AIDS Treatment Assistance Program, May 7, 2007. Gerber JG, Kiser JJ. Pharmacology Update from the 14th Conference on Retroviruses and Opportunistic Infections. National AIDS Treatment Assistance Program, March 14, 2007. Anderson PL, Kiser JJ. Medscape HIV/AIDS. Pharmacologic review of the 6th International Workshop on Clinical Pharmacology of HIV Therapy. April 28 – 30, 2005, Quebec City, Canada. 2005. (Available at: http://www.medscape.com/hiv-aidshome?src=pdown) Kiser JJ. Kaletra™. Positively Aware: The Eight Annual HIV Drug Guide; Jan-Feb 2004:30. Justice JA. Acutely Decompensated CHF. Discourse Sept-Oct 2001;23(5):19-20. Justice JA. Turning Threats and Challenges to Pharmacy into Opportunities for the Profession. North Carolina Pharmacist 2000;80(4):20. OTHER ACTIVITIES 2008 to present Associate Director for Pharmacokinetics, University of Colorado Denver School of Pharmacy Center for Translational Pharmacokinetic and Pharmacogenetic Research 7/2008 to 7/2009 Organizing Committee for the 4th International Workshop on Clinical Pharmacology of Hepatitis Therapy, Boston, MA June 2009 8/2009 to 7/2010 Co-Chair, Organizing Committee for the 5th International Workshop on Clinical Pharmacology of Hepatitis Therapy, Boston, MA June 2010 Jennifer J. Kiser, PharmD Page 9 of 9 06/30/17